6hf5
From Proteopedia
(Difference between revisions)
m (Protected "6hf5" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal Structure of the Acquired VIM-2 Metallo-beta-Lactamase in Complex with ANT-431 Inhibitor== | |
| + | <StructureSection load='6hf5' size='340' side='right' caption='[[6hf5]], [[Resolution|resolution]] 1.80Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6hf5]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6HF5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6HF5 FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=G1N:5-(pyridin-3-ylsulfonylamino)-1,3-thiazole-4-carboxylic+acid'>G1N</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5mxq|5mxq]], [[5mxr|5mxr]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6hf5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6hf5 OCA], [http://pdbe.org/6hf5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6hf5 RCSB], [http://www.ebi.ac.uk/pdbsum/6hf5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6hf5 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The clinical effectiveness of carbapenem antibiotics such as meropenem is becoming increasingly compromised by the spread of both metallo-beta-lactamase (MBL) and serine-beta-lactamase (SBL) enzymes on mobile genetic elements, stimulating research to find new beta-lactamase inhibitors to be used in conjunction with carbapenems and other beta-lactam antibiotics. Herein, we describe our initial exploration of a novel chemical series of metallo-beta-lactamase inhibitors, from concept to efficacy, in a survival model using an advanced tool compound (ANT431) in conjunction with meropenem. | ||
| - | + | SAR Studies Leading to the Identification of a Novel Series of Metallo-beta-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model.,Leiris S, Coelho A, Castandet J, Bayet M, Lozano C, Bougnon J, Bousquet J, Everett M, Lemonnier M, Sprynski N, Zalacain M, Pallin TD, Cramp MC, Jennings N, Raphy G, Jones MW, Pattipati R, Shankar B, Sivasubrahmanyam R, Soodhagani AK, Juventhala RR, Pottabathini N, Pothukanuri S, Benvenuti M, Pozzi C, Mangani S, De Luca F, Cerboni G, Docquier JD, Davies DT ACS Infect Dis. 2018 Nov 30. doi: 10.1021/acsinfecdis.8b00246. PMID:30427656<ref>PMID:30427656</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| + | <div class="pdbe-citations 6hf5" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Benvenuti, M]] | ||
| + | [[Category: Docquier, J D]] | ||
| + | [[Category: Luca, F De]] | ||
| + | [[Category: Mangani, S]] | ||
| + | [[Category: Pozzi, C]] | ||
| + | [[Category: Alpha-beta-beta-alpha sandwich]] | ||
| + | [[Category: Hydrolase]] | ||
| + | [[Category: Metallo-beta-lactamase fold]] | ||
| + | [[Category: Pfam00753]] | ||
| + | [[Category: Zinc-dependent hydrolase]] | ||
Revision as of 06:46, 5 December 2018
Crystal Structure of the Acquired VIM-2 Metallo-beta-Lactamase in Complex with ANT-431 Inhibitor
| |||||||||||
